Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Posted on: Jun 09, 2022

Play Episode

Also available on

Spotify

Apple Podcasts

Overview

Kendra Sweet, MD
Moffitt Cancer Center
Interview Date: June 9, 2022

Immunotherapy continues to be an expanding and evolving area of research for AML with many drugs in development. In this show, Dr. Kendra Sweet, an AML expert from Moffitt Cancer Center, shared with us about an antibody drug conjugate called IMGN632 and the current trials using this drug. IMGN632 targets CD123-positive AML cells and has shown promising results in relapsed/refractory patients in previous AML trials.

Thanks to Our Episode Sponsor

User uploaded media

On this episode

Kerith Amen

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.

Kendra Sweet, MD

Dr. Kendra Sweet is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sweet's clinical interests include myeloid malignancies with a particular focus on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Transcript

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Thanks to Our Episode Sponsor

Related Content